Long-term safety and efficacy of intramyocardial adenovirus-mediated VEGF-D(ΔNΔC) gene therapy eight-year follow-up of phase I KAT301 study

In phase I KAT301 trial, intramyocardial adenovirus-mediated vascular endothelial growth factor -D(ΔNΔC) (AdVEGF-D) gene therapy (GT) resulted in a significant improvement in myocardial perfusion reserve and relieved symptoms in refractory angina patients at 1-year follow-up without major safety con...

Descripción completa

Detalles Bibliográficos
Autores principales: Leikas, Aleksi J., Hassinen, Iiro, Hedman, Antti, Kivelä, Antti, Ylä-Herttuala, Seppo, Hartikainen, Juha E. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159942/
https://www.ncbi.nlm.nih.gov/pubmed/34593990
http://dx.doi.org/10.1038/s41434-021-00295-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159942/
https://www.ncbi.nlm.nih.gov/pubmed/34593990
http://dx.doi.org/10.1038/s41434-021-00295-1

Ejemplares similares